Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present its Deciparticle (TM) nanomedicine platform and clinical pipeline at BIO-Europe Spring 2026 on March 25, where it has been selected as a presenting company. The company will highlight its next-generation drug delivery technology along with two lead candidates, Sapu003 (Everolimus for Injection), currently in Phase 1 trials, and Sapu006 (Docetaxel for Injection), entering Phase 1, as it seeks strategic partnerships to advance development and commercialization.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer